10x Genomics(US:TXG) Prnewswire·2026-01-12 14:00Core Insights - 10x Genomics, in collaboration with the Cancer Research Institute (CRI), is launching a multi-phase initiative to generate high-resolution molecular data from over 20,000 samples to enhance immuno-oncology research and develop new immunotherapies and vaccines [1][4]. Group 1: Project Overview - The initiative will start with a pilot phase involving leading researchers from top immuno-oncology laboratories, aiming to generate approximately 3,000 samples using 10x's Chromium and Xenium platforms [2]. - The full project phase will expand to a broader network of laboratories, utilizing 10x's Chromium Flex single cell assay to profile over 500 million cells [3]. Group 2: Objectives and Impact - The integrated dataset will help uncover mechanisms of immune response and resistance, refine existing treatments, and identify new therapeutic strategies, ultimately contributing to vaccine discovery [4]. - This collaboration aims to create a high-resolution immune atlas that can redefine cancer prevention and treatment strategies [5]. Group 3: Company Background - 10x Genomics is a life science technology company focused on advancing human health through products that enable researchers to understand biological systems at a high resolution and scale [7]. - The Cancer Research Institute, established in 1953, is dedicated to advancing immunotherapy research and has invested over $560 million in related studies [9].